echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > "Pharmaceutical Express" sHTG candidate drug Phase 3 clinical failure Yuandong Biotech board listed

    "Pharmaceutical Express" sHTG candidate drug Phase 3 clinical failure Yuandong Biotech board listed

    • Last Update: 2020-11-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    September 2, 2020 / Medical Information List: $20 million advance AstraZeneta expands vaccine production partnership with Oxford; Gilead and Jounce reach $800 million partnership; Shishi Meishi-Guibao Onureg is approved by the FDA; AstraZeneta Imfinzi's first-line treatment for broad-term small cell lung cancer is approved by the European Union... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief official documents announced: Severe punishment of doctors, Sichuan Provincial Administration of Traditional Chinese Medicine official website issued "on the further strengthening of social-run medical institutions in accordance with the law practice management notice", proposed to crack down on social-run medical institutions, doctors to buy, sell, transfer, lease related qualifications.
    (Sichuan Provincial Administration of Traditional Chinese Medicine) Part 2 production by observation garden East Biology Today's science and trot board listing yuan east biology officially in the science board bell-ringing listed.
    According to the prospectines disclosed, the IPO, Yuandong Bio intends to issue 30.09 million new shares at the issue price of 44.36 yuan, raising 1,161 million yuan for major diseases in the field of innovative drug products industrialization base construction, pharmaceutical clinical research and biological drug research and development projects.
    (Medical Rubik's Cube) Wu Qiong left Merca East 1 pm, Merca East China President Luo Wanli announced to employees, Merca East China Hospital Specialist Medical Division (HSCBU) head Wu Qiong has decided to leave Merca East, seeking external development opportunities.
    the departure of Wu Qiong, the successor has been determined, from today, will be replaced by the current head of the business operations team, Ma Qi, as head of HSCBU.
    (Pharmaceutical Representative) Chen Zhicheng joined Roche recently, Roche Pharmaceuticals China announced to employees the news of Chen Zhicheng's entry, from September 7, he will join Roche Pharmaceuticals China Oncology Division II, as head of the field of lung cancer disease, directly reported to BUO2 Chen Shaofeng Vice President.
    (Pharmaceutical Representative) prepaid $20 million for AstraZeneca to expand its vaccine production partnership with Oxford, and AstraZeneca will pay Oxford an initial fee of $20 million to meet the adenovirus COVID-19 vaccine AZD1222's production capacity of up to 1000 liters for at least 18 months.
    the agreement for a period of three years, with an additional 18 months of retention in addition to the required 18-month supply period.
    announced an $800 million partnership with Jounce on Monday to obtain exclusive research and development licenses for its JTX-1811 project.
    terms of the agreement, Gilead will make an $85 million advance payment to Jones and make a $35 million equity investment.
    addition, Jounce is expected to receive up to $685 million in follow-up payments in the future based on clinical, regulatory and commercial milestones.
    a new round of equity financing of $35 million, including Felicis Ventures and Amplify Partners, announced the completion of a new round of equity financing of $35 million.
    Picnic Health will use the current round of funding to enter new areas of disease, expand access to the platform to more patients with different diseases, and build new research data sets.
    (Xinhua) -- CaPre®, a candidate prescription drug for the treatment of severe high triglycerideemia (sHTG), announced on August 31st that another Phase 3 clinical study, TRILOGY 2, had failed, after the failure of a Phase 3 clinical trial of the trial drug was announced in January®.
    news led directly to a 60 per cent plunge in Acasti's shares.
    (Sina Pharmaceutical News) AstraZeneca Imfinzi first-line treatment of broad-stage small cell lung cancer was approved by the European Union, AstraZeneca announced that Imfinzi combined etoposide and carptonin or cisplatin for first-line treatment of adult wide-stage small cell lung cancer was approved by the European Union to market.
    that Imfinzi's combination therapy for the disease had been recommended by the European Medicines Agency's Commission on Human Use as early as July.
    Imfinzi is an humanized PD-L1 monoclonal antibody that blocks the binding of PD-L1 to PD-1 and CD80, thereby blocking tumor immune escape and releasing suppressed immune responses.
    (Sina Pharmaceutical News) Hundred Times Zeposia treatment of multiple sclerosis with long-term efficacy and safety Shishi Shiguibao recently announced multiple at MSVirtual 2020 General Assembly 8th Joint ACTRIMS-ECTRIMS Conference The medium-term results of the new sclerosis drug Zeposia 3 Open Label Extension Trial DAYBREAK confirm Zeposia's long-term efficacy and safety for patients with multiple sclerosis: most patients do not relapse during the 24th and 36th months of treatment without new safety issues.
    (Bio Valley) Hundreds of Centroughs Onureg has been approved by the U.S. FDA for the listing of The Company's Onureg as a continuing treatment for adult acute myeloid leukemia patients who have received their first complete remission (CR) or CR blood cell count incomplete remission after strong induced chemotherapy.
    (Pharmaceutical Mingkangde) innovative oral yew alcohol formula by the FDA priority review qualification treatment metastasis breast cancer Atsenex announced that the FDA has accepted the company for oral yew alcohol to submit a new drug application, and granted it priority review qualification, the adaptive disease is metastametic breast cancer.
    THE FDA expects to respond by February 28 next year.
    , the FDA said it had no plans to convene an advisory committee to discuss the request.
    Vertex has been accepted by the FDA to treat more CF patients, Vertex announced recently, the FDA has accepted Trikafta, Symdeko, Kalydeco three applications for new drugs (sNDA).
    These sNDAs are designed to expand the labeling of Trikafta, Symdeko, and Kalydeco to include additional rare CFTR mutations that give patients with cystic fibrosis (CF) who were previously ineligible for these drugs the opportunity to benefit from treatment for the underlying causes of their disease.
    (Bio Valley) No. and Nord Sogroya are FDA approved by the FDA for the treatment of growth hormone deficiency in adults The FDA recently approved No.
    in treating adult GHD, Sogroya is the first human growth hormone therapy to be injected only once a week, while other FDA-approved hGH preparations must be injected daily.
    (Bio Valley) Mylan/Baikang long-acting insulin in the U.S. before the U.S. market, Mylan/Baikang long-acting insulin has obtained FDA approval to start the U.S. market Semglee.
    purchase cost (WAC) of five 3 ml injection pens per pack is $147.98 and the WAC for a 10 ml vial is $98.65.
    makes Semglee the cheapest long-acting insulin glycelin on the U.S. market.
    (Sina Pharmaceutical News) Zhongsheng Pharmaceutical Breast Cancer Drug "Fluvis Group Injection" by the drug registration certificate 1, Zhongsheng Pharmaceutical announced that the group developed the treatment of breast cancer drug "Fluvis Group Injection" (commodity name: Qingcoyi) has been issued by the State Drug Administration drug registration certificate, the first approval of the variety, and as the same through generic quality and efficacy consistent evaluation.
    can be in accordance with the chemical drugs in the new 4 categories of declaration, was included in the "first batch of encouraging generic drugs directory."
    (Zhongsheng Pharmaceutical Announcement) Bibet Pharmaceuticals Class 1 new drug ZXBT-1158 capsules approved clinical CDE latest publicity, by Bibet Pharmaceuticals and Xinxing Bett Pharmaceuticals jointly developed innovative 1 new drug ZXBT-1158 capsules obtained two clinical trials implied permission, intended to be developed for the treatment of late-stage recurrence difficult to treat B cell malignancies.
    this is the first time the product has been approved clinically in China as a second-generation BTK inhibitor.
    (Pharmaceutical Mission) Xi'an Libang pharmaceutical fluorobilofen ester injection class 3 imitation application for listing Xi'an Libang pharmaceutical fluorobilofen ester injection class 3 generic market application was accepted by CDE.
    the product for the first batch of national collection catalog varieties.
    from CDE's official website data, Xi'an Libang Pharmaceuticals in 2014 also declared the listing, when 6 types of imitations were finally approved clinical, and now according to 3 types of imitations declared listed, if successfully approved is treated as a review.
    (Minenet) health yuan isopropyl bromide inhalation solution 4 imitation is about to be approved, health yuan subsidiary Shenzhen Mrs. Pharmaceuticals isopropyl bromide inhalation solution 4 imitation listing application entered the "in the approval" stage, is expected to be approved in the near future.
    isopropyl bromide inhalants are used for the maintenance of bronchopulmonary spasms caused by chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
    (Mienet)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.